Kala Bio (KALA) Stock
Small biotechnology company developing new medical treatments. Here's the price, business snapshot, and what's worth knowing about Kala Bio in October 2026.
KALA BIO Inc (KALA) is a very small-cap biotechnology company with a market capitalisation of about $6.53 million. As a microcap in the biotech space, it is likely to be driven by clinical progress, regulatory milestones, licensing activity and occasional financing events. Such stocks can offer substantial upside if development programmes succeed, but they also carry heightened risks: limited liquidity, significant volatility, and dependence on external capital. Prospective investors should review the company’s regulatory filings, cash runway, pipeline updates and recent investor presentations to understand timing and likelihood of key catalysts. This summary is for general educational purposes only — not personalised advice. Values can rise and fall, and past performance is no guarantee of future returns. Consider your own risk tolerance and, if needed, consult a regulated financial adviser before making investment decisions.
Kala Bio (KALA) Stock Forecast
Analyst price target, next 12 months
$22.00
+5614.3% vs today's $0.39
Price range over the last 12 months
Close to its 12-month low
Analysts covering Kala Bio have a consensus 12-month target of $22.00, above the current price of $0.39.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 24 Jul 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying KALA Bio's stock with a target price of $22, indicating significant potential growth.
Financial Health
KALA Bio Inc shows moderate financial performance with reasonable book value and cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress in trials or approvals can be a key value driver, though outcomes are uncertain and timing can shift.
Financing Sensitivity
Small biotech firms often need fresh capital; fundraising can dilute existing holders and influence the share price.
Research Due Diligence
Check filings, cash runway and management commentary to understand catalysts and the company’s strategic direction.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
